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bacter spp., classic pathogens ofinvasive dysenteric disease, are isolated in 1-
15% of cases. Vibrio species are most common in Asia. Less common
bacteria are Aeromonas hydrophila and Plesiomonas shigelloides. Parasitic
causes of TD include E. histolytica, G. lamblia and Cryptosporidium.
Viruses such as Rotavirus and Norwalk-like Virus have been isolated
from up to 12% of visitors to Latin America, Asia and Africa. The most
pragmatic approach to the prevention ofTD is the advice to "cook it, boil it,
peel it, or forget it". Prophylaxis with antinticrobials has been shown to be of
benefit in preventing TD with Trimethoprim-sulfamethoxazole and /luor-
oquinolones, but the routine use of these agents is generally not recom-
mended because of sideeffects of antibiotics and the development of
resistance. Antimicrobial prophylaxis can be discussed in patients with
inflammatory bowel disease, immunocompromised patients (HIV-infected
persons or transplant recipients) or patients for whom dehydration would be
dangerous. The mainstay of treatment is adaequate rehydration with oral
rehydration solution ev. supplemented with loperantide. Antimicrobials are
indicated in patients with severe abdominal pain, fever or dysentcry.
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Over the past decade, antibiotic efflux systems have been discovered in a
growing number ofbacterial pathogens. Extensive studies on Escherichia coli,
Pseudomonas aeruginosa and Neisseria gono"hoeae have led to the conclusion
that efflux pumps of the RND fantily play an essential role in the natural
resistance of these species to a vast array of inhibitors. For example, the
elevated intrinsic resistance ofP. aeruginosa to antibiotics mainly depends on
the expression of two poorly specific export systems (MexAB-OprM and
MexXY), the action of which is potentiated by the outer membrane
permeability barrier. In pathogens exhibiting more permeable outer mem-
branes, such as E. coli, efflux systems provide an efficient protection against
large or hydrophobic compounds (e.g. bile acids, defensins, and macrolides).
When overexpressed following mutations in regulatory genes, RND
pumps may produce clinically relevant resistance to a great many substrate
antibiotics (MICs x 2-16). Such efflux mutants have frequendy been
reported among clinical strains of P. aeruginosa. According to concordant
data, MexAB-OprM overproducers would account for 30 to 70% of the
carbenicillin resistance in hospital strains. The virulence status of the efflux
mutants however requires further investigations.
As demonstrated in E. coli and P. aeruginosa, efflux systems may have a
major impact on bacterial resistance when they are combined with other
mechanisms such as target alterations (DNA gyrase) or ,B-Iactamase produc-
tion. Furthermore, active export of antibiotics tends to increase the emer-
gence of highly resistant target mutants. For all these reasons, efBux
inhibitors would be invaluable drugs in the treatment of infections caused
by multidrug resistant strains.
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Efflux pumps are now well recognised in a number of Gram-positive
bacteria. The role of these pumps in normal physiology is unclear, but
their increased expression produces low-level antibiotic resistance Their role,
in combination with other resistance mechanisms, in producing clinical
significant resistance in is becoming increasingly important. Pumps which
appear to have a limited substrate range are macrolide pumps such as mefA
(Streptococcus pyogenes), mejE (Streptococcus pneumoniae) and mreA (Strepto-
coccus agalactiae) or the some oftet determinants (eg, tetK and tetL). The best
characterised pump in Staphylococcus aureus is NorA. Although Nora is
associated with quinolone resistance, it can use a wide range of substrates.
PmrA of Streptococcus pneumoniae is a pump similar to NorA. NorA and
PrnrA show structural and functional similarities to the efflux pumps Bmr
and Bit of Bacillus subtilis. However, it is likely that the regulation of Nora
and PmrA is different. Genome sequencing projects have indicated that
homologues to existing characterised pumps are found in a wide range of
bactena, Several pump. may exi.t in the .ame .train; homologues of Bmr,
Bit and EmrAB have been found in addition to Nora in a strain of
Staphylococcus aureus. Drugs which are not affected by efflux-mediated
resistance are being developed. Pump inhibitors are also being researched.
Efflux pumps can contribute to intrinsic antibiotic resistance. Their inactiva-
tion in different species is being developed as a sensitive tool for screening for
naturally occurring antimicrobial agents that would otherwise be effluxed
from the cell.
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Mechanisms of resistance in yeasts and fungi are various and yet incomple-
tely worked out. Efflux pumps are implicated so far in acquired azole
resistance among yeasts, particularly Candida a/bicans, as well as some other
Candida species: C. glabrata, C. krusei, C. dublinimsis, C. tropicalis.
Evidence for their direct implication as mechanisms ofacquired resistance
in isogenie pairs or series ofclinical strains with increasing levels ofresistance
to fluconazole (F) are the following: i) increase efflux of azoles, as well as
other substrates of MDR transporters (rhodamine); ii) increase of mRNA
levels for MDR genes (CDR or MDR); iii) MDR gene over-expression in S.
cerevisiae confers resistance; iv) MDR gene deletion in C. albicans results in an
hypersusceptible strain.
So far, several efflux transporter genes have been characterised, belonging
either to the ATB Binding Cassette (CDR genes) or to the Major Facilitator
(BENr, FLU genes) transporters, conferring various degrees of cross-
resistance to azoles or other substrate•.
Clinical significance of efflux pumps mediated resistance in yeasts (parti-
cularly C. albicans) has been largely documented mainly in Aids patients
suffering from oropharyngeal candidiasis (OPC), particularly before
HAART. In other clinical settings, few cases have undoubtedly been
described where clinical resistance was correlated to acquired efBux mediated
F resistance after a short course of F. In a rat model ofendocarditis due to C.
albicans, inhibition of the efflux resistance mechanism by cyclosporin not
only restored the efficacy ofF to cure infection due to a F-resistant strain, but
also afforded significant better results than F alone when the strain was F-
susceptible.
Thus combining clinically administrable efflux pumps inhibitors to azoles
should be sought in order to improve the efficacy ofthis class ofantifungals.
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The recent description of intermediate (homogeneous and heterogeneous)
glycopeptide-resistance of Staphylococcus aureus (GISA) has raised concern
about the importance of this potential public heath problem. However, the
emergence of GISA i. not a new phenomenon. Teicoplanin-resistant
mutants of S. aureus selected in vitro have been reported in severallabora-
tories since 1990. These studies have shown that teicoplanin was a more
efficient selective agent than vancomycin, even if more recently a highly
vancomycin-resistant mutant (MIC = 100 p.g/ml) of S. aureus has been
selected by Sieradzki et al. O. Bacteriol. 1997; 179: 2557-2566) by a step-wise
pressure procedure with vancomycin. The first in vivo emergence of
teicoplanin resistance, during therapy, of S. aureus has also been reported
in 1990 (Kaatzet al. J. Infect. Dis. 1990; 162: 103-108) and in several studies
since. The isolation of GISA strains, often in patients which have received
prolonged therapy with glycopeptides, and the possibility to select mutants
from hetero-GISA with further increased resistance to glycopeptides, both in
vitro and in vivo, underline the necessity to monitor carefully the serum levels
of glycopeptide during therapy.
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